Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history

» Details

Guru Trades

Q3 2015

IXJ Guru Trades in Q3 2015

Ken Fisher 19,213 sh (+187.71%)
» More
Q4 2015

IXJ Guru Trades in Q4 2015

Ken Fisher 92,228 sh (+380.03%)
» More
Q1 2016

IXJ Guru Trades in Q1 2016

Ken Fisher 12,122 sh (-86.86%)
» More
Q2 2016

IXJ Guru Trades in Q2 2016

Ken Fisher 17,624 sh (+45.39%)
» More

Ratios

vs
industry
vs
history
P/E(ttm) 22.83
IXJ's P/E(ttm) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IXJ: 22.83 )
Ranked among companies with meaningful P/E(ttm) only.
IXJ' s P/E(ttm) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 24.36
Current: 22.83
0
24.36
PE(NRI) 22.83
IXJ's PE(NRI) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IXJ: 22.83 )
Ranked among companies with meaningful PE(NRI) only.
IXJ' s PE(NRI) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 24.36
Current: 22.83
0
24.36
P/B 3.55
IXJ's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IXJ: 3.55 )
Ranked among companies with meaningful P/B only.
IXJ' s P/B Range Over the Past 10 Years
Min: 0  Med: 0 Max: 3.68
Current: 3.55
0
3.68

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.85
IXJ's Dividend Yield is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IXJ: 1.85 )
Ranked among companies with meaningful Dividend Yield only.
IXJ' s Dividend Yield Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.88
Current: 1.85
0
1.88
Yield on cost (5-Year) 1.85
IXJ's Yield on cost (5-Year) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IXJ: 1.85 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
IXJ' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.88
Current: 1.85
0
1.88

More Statistics

Short Percentage of Float0.00%
52-Week Range $89.70 - 106.25
Shares Outstanding (Mil)15,500,000.00
» More Articles for IXJ

Headlines

Articles On GuruFocus.com
Twitter Considering Buyout Sep 26 2016 
Presidential Debate a Factor for the Market This Week Sep 26 2016 
Newmont Determined to Acquire Barrick's Stake in the Super Pit Sep 26 2016 
Gurus Invest in Undervalued Retail Companies Sep 26 2016 
Yelp CEO Sells Shares in Company Sep 26 2016 
Tom Russo's 1st Quarter Semper Vic Partners Investor Letter Sep 26 2016 
Tom Russo Comments on MasterCard Sep 26 2016 
Tom Russo Comments on Wells Fargo Sep 26 2016 
Tom Russo Comments on Compagnie Financièr Richemont, SA Sep 26 2016 
Deutsche Bank Is Over-Leveraged Sep 26 2016 

More From Other Websites
AstraZeneca Is Taking Steps to Improve Its Position in Oncology Sep 19 2016
Roche Sees Soaring Revenue from Its Bladder Cancer Treatment Sep 16 2016
What Investors Can Glean from GlaxoSmithKline’s Revenue Trend Sep 09 2016
Is Johnson & Johnson’s Valuation High Compared to Its Peers? Aug 30 2016
[$$] Why Investors Should Think Global Aug 26 2016
AstraZeneca’s Recent Product Developments Aug 25 2016
AstraZeneca and Its Oncology Segment’s Growth in 2Q16 Aug 25 2016
How Crestor Weakened AstraZeneca’s CVMD Segment in 2Q16 Aug 24 2016
Remicade Is Driving Down Merck’s Immunology Franchise Aug 16 2016
How Are Eli Lilly’s New Products Performing? Aug 04 2016
Revenues from Eli Lilly’s Cymbalta Are Depressed Internationally Aug 03 2016
What to Expect from Pfizer’s 2Q16 Earnings Aug 01 2016
How Did JNJ’s Pharmaceutical Segment Fare in 2Q16? Jul 22 2016
Understanding Lilly’s New Product Expectations for 2Q16 Jul 22 2016
Inside Lilly’s 2Q16 Estimates for Its Neuroscience Franchise Jul 22 2016
Why AbbVie Continues to Explore Imbruvica for Diffuse Large B-Cell Lymphoma Jul 06 2016
AstraZeneca’s Key Focus: Oncology Jun 06 2016
What’s AstraZeneca’s Largest Revenue Contributor? Jun 01 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK